Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...

Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.

Eton Pharma gets US patent covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution: Deer Park, Illinois Monday, February 10, 2025, 11:00 Hr ...

Eton Pharmaceuticals (ETON) announced that the United States Patent and Trademark Office has granted the company U.S. Patent No. 12,214,010, ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...

Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...

The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL): Mr.

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

Q4 2024 Earnings Call Transcript February 7, 2025 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.12 ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

The authorities could allow the country’s currency, the peso, to weaken against the dollar, effectively making its exports ...

Appellate courts issued a variety of notable intellectual property (IP) cases in 2024, including cases touching on Orange Book ...